KDM2A

Lysine-specific demethylase 2A · Q9Y2K7 · KDM2A on Sugi Atlas →

38,762 patent compounds predicted against KDM2A, 21,000 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL50347	1.00	8/20
Levulinic Acid (SCHEMBL113572)	0.60	7/20
Levulinic Acid (SCHEMBL377114)	0.55	7/20
Succinic Acid (SCHEMBL173955)	0.52	7/20
SCHEMBL167219	0.52	7/20
Succinic Acid (SCHEMBL209622)	0.48	7/20
SCHEMBL318778	0.42	7/20
SCHEMBL318779	0.42	7/20
Bromide (SCHEMBL313907)	0.97	6/20
Bromide (SCHEMBL313908)	0.97	6/20
Dipyridyl (SCHEMBL213432)	0.70	6/20
Bromide (SCHEMBL284742)	0.67	6/20
Bromide (SCHEMBL285125)	0.67	6/20
SCHEMBL218098	0.65	6/20
Succinic Acid (SCHEMBL35204)	0.58	6/20
SCHEMBL83586	0.53	6/20
SCHEMBL94233	0.50	6/20
SCHEMBL223005	0.50	6/20
SCHEMBL70700	0.78	5/20
Iodide (SCHEMBL285057)	0.72	5/20

Clinical trials — most relevant to KDM2A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2	PHASE2	ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans	nan	ACTIVE_NOT_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19	nan	COMPLETED
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia	nan	UNKNOWN
The Danish TURNER Cryopreservation Study	nan	RECRUITING
OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia	nan	RECRUITING
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Genetic Study of Familial Factors in Patients With Colon Cancer	nan	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy	nan	UNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy	nan	COMPLETED
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
The Crosstalk Between the Epigenome and Mitochondria in SCI	nan	NOT_YET_RECRUITING
Mechanisms of Immune Deficiency	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a KDM2A binder may also engage these)

Protein	Name	Similarity
P59997	—	1.000	P59997 →
Q5U263	—	0.994	Q5U263 →
KDM2B	Lysine-specific demethylase 2B	0.991	landscape →
Q5RHD1	—	0.991	Q5RHD1 →
Q5TKR9	—	0.991	Q5TKR9 →
Q8WML3	—	0.991	Q8WML3 →
Q92613	—	0.990	Q92613 →
Q08D35	—	0.990	Q08D35 →
Q9JHD2	—	0.990	Q9JHD2 →
Q1LYM3	—	0.990	Q1LYM3 →
Q1ECV4	—	0.989	Q1ECV4 →
Q9Y4B4	—	0.989	Q9Y4B4 →
Q8BMD7	—	0.988	Q8BMD7 →
MAP3K9	Mitogen-activated protein kinase kinase kinase 9	0.988	landscape →
Q6P1G2	—	0.988	Q6P1G2 →
Q08AX9	—	0.988	Q08AX9 →
Q6ZPS6	—	0.988	Q6ZPS6 →
Q9Z2R9	—	0.988	Q9Z2R9 →
Q68FF0	—	0.988	Q68FF0 →
Q5JCS6	—	0.988	Q5JCS6 →
KAT2B	Histone acetyltransferase KAT2B	0.988	landscape →
Q9VHH9	—	0.988	Q9VHH9 →
E9PUQ8	—	0.988	E9PUQ8 →
Q8R0S2	—	0.988	Q8R0S2 →
KDM4B	Lysine-specific demethylase 4B	0.987	landscape →
D3YWQ0	—	0.987	D3YWQ0 →
Q6IVY4	—	0.987	Q6IVY4 →
Q9BQI7	—	0.987	Q9BQI7 →
Q803A0	—	0.987	Q803A0 →
Q640I9	—	0.987	Q640I9 →